Gaucher Disease
"Gaucher Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.
Descriptor ID |
D005776
|
MeSH Number(s) |
C10.228.140.163.100.435.825.400 C16.320.565.189.435.825.400 C16.320.565.398.641.803.441 C16.320.565.595.554.825.400 C18.452.132.100.435.825.400 C18.452.584.687.803.441 C18.452.648.189.435.825.400 C18.452.648.398.641.803.441 C18.452.648.595.554.825.400
|
Concept/Terms |
Gaucher Disease- Gaucher Disease
- Disease, Gaucher
- Acid beta-Glucosidase Deficiency Disease
- Acid beta Glucosidase Deficiency Disease
- Cerebroside Lipidosis Syndrome
- Cerebroside Lipidosis Syndromes
- Lipidosis Syndrome, Cerebroside
- Lipidosis Syndromes, Cerebroside
- Syndrome, Cerebroside Lipidosis
- Syndromes, Cerebroside Lipidosis
- Glucocerebrosidase Deficiency
- Deficiencies, Glucocerebrosidase
- Deficiency, Glucocerebrosidase
- Glucocerebrosidase Deficiencies
- Glucocerebrosidase Deficiency Disease
- Deficiency Disease, Glucocerebrosidase
- Deficiency Diseases, Glucocerebrosidase
- Disease, Glucocerebrosidase Deficiency
- Diseases, Glucocerebrosidase Deficiency
- Glucocerebrosidase Deficiency Diseases
- Glucosylceramide Beta-Glucosidase Deficiency Disease
- Glucosylceramide Beta Glucosidase Deficiency Disease
- Acid beta-Glucosidase Deficiency
- Acid beta Glucosidase Deficiency
- Acid beta-Glucosidase Deficiencies
- Deficiencies, Acid beta-Glucosidase
- Deficiency, Acid beta-Glucosidase
- Gaucher's Disease
- Disease, Gaucher's
- Gauchers Disease
Gaucher Disease, Type 2- Gaucher Disease, Type 2
- Gaucher Disease Type 2
- Gaucher Disease, Acute Neuronopathic
- Gaucher Disease, Type II
- Gaucher Disease, Infantile
- Disease, Infantile Gaucher
- Gaucher Disease, Infantile Cerebral
- Infantile Gaucher Disease
- Type 2 Gaucher Disease
- Acute Neuronopathic Gaucher Disease
- Gaucher Disease, Acute Neuronopathic Type
Gaucher Disease, Type 3- Gaucher Disease, Type 3
- Gaucher Disease Type 3
- Gaucher Disease, Chronic Neuronopathic Type
- Gaucher Disease, Juvenile
- Disease, Juvenile Gaucher
- Juvenile Gaucher Disease
- Type 3 Gaucher Disease
- Gaucher Disease, Neuronopathic
- Disease, Neuronopathic Gaucher
- Gaucher Disease, Subacute Neuronopathic Form
- Gaucher Disease, Subacute Neuronopathic Type
- Neuronopathic Gaucher Disease
- Subacute Neuronopathic Gaucher Disease
- Gaucher Disease, Type III
- Gaucher Disease, Juvenile and Adult, Cerebral
Gaucher Disease, Type 1- Gaucher Disease, Type 1
- Gaucher Disease Type 1
- Gaucher Disease, Chronic
- GBA Deficiency
- Deficiencies, GBA
- Deficiency, GBA
- GBA Deficiencies
- Gaucher Disease, Noncerebral Juvenile
- Gaucher Disease, Type I
- Non-Neuronopathic Gaucher Disease
- Disease, Non-Neuronopathic Gaucher
- Gaucher Disease, Non-Neuronopathic
- Non Neuronopathic Gaucher Disease
- Type 1 Gaucher Disease
- Chronic Gaucher Disease
- Disease, Chronic Gaucher
- Gaucher Disease, Non-Neuronopathic Form
- Gaucher Disease, Non Neuronopathic Form
|
Below are MeSH descriptors whose meaning is more general than "Gaucher Disease".
- Diseases [C]
- Nervous System Diseases [C10]
- Central Nervous System Diseases [C10.228]
- Brain Diseases [C10.228.140]
- Brain Diseases, Metabolic [C10.228.140.163]
- Brain Diseases, Metabolic, Inborn [C10.228.140.163.100]
- Lysosomal Storage Diseases, Nervous System [C10.228.140.163.100.435]
- Sphingolipidoses [C10.228.140.163.100.435.825]
- Gaucher Disease [C10.228.140.163.100.435.825.400]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Metabolism, Inborn Errors [C16.320.565]
- Brain Diseases, Metabolic, Inborn [C16.320.565.189]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.189.435]
- Sphingolipidoses [C16.320.565.189.435.825]
- Gaucher Disease [C16.320.565.189.435.825.400]
- Lipid Metabolism, Inborn Errors [C16.320.565.398]
- Lipidoses [C16.320.565.398.641]
- Sphingolipidoses [C16.320.565.398.641.803]
- Gaucher Disease [C16.320.565.398.641.803.441]
- Lysosomal Storage Diseases [C16.320.565.595]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.595.554]
- Sphingolipidoses [C16.320.565.595.554.825]
- Gaucher Disease [C16.320.565.595.554.825.400]
- Nutritional and Metabolic Diseases [C18]
- Metabolic Diseases [C18.452]
- Brain Diseases, Metabolic [C18.452.132]
- Brain Diseases, Metabolic, Inborn [C18.452.132.100]
- Lysosomal Storage Diseases, Nervous System [C18.452.132.100.435]
- Sphingolipidoses [C18.452.132.100.435.825]
- Gaucher Disease [C18.452.132.100.435.825.400]
- Lipid Metabolism Disorders [C18.452.584]
- Lipidoses [C18.452.584.687]
- Sphingolipidoses [C18.452.584.687.803]
- Gaucher Disease [C18.452.584.687.803.441]
- Metabolism, Inborn Errors [C18.452.648]
- Brain Diseases, Metabolic, Inborn [C18.452.648.189]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.189.435]
- Sphingolipidoses [C18.452.648.189.435.825]
- Gaucher Disease [C18.452.648.189.435.825.400]
- Lipid Metabolism, Inborn Errors [C18.452.648.398]
- Lipidoses [C18.452.648.398.641]
- Sphingolipidoses [C18.452.648.398.641.803]
- Gaucher Disease [C18.452.648.398.641.803.441]
- Lysosomal Storage Diseases [C18.452.648.595]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.595.554]
- Sphingolipidoses [C18.452.648.595.554.825]
- Gaucher Disease [C18.452.648.595.554.825.400]
Below are MeSH descriptors whose meaning is more specific than "Gaucher Disease".
This graph shows the total number of publications written about "Gaucher Disease" by people in UAMS Profiles by year, and whether "Gaucher Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2020 | 1 | 0 | 1 | 2019 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 | 2017 | 3 | 0 | 3 | 2016 | 1 | 0 | 1 | 2015 | 3 | 0 | 3 | 2014 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 1998 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Gaucher Disease" by people in Profiles over the past ten years.
-
Abell K, Chadwell SE, Burrow TA, Becker APP, Bailey L, Steele P, Zhang X, Islas-Ohlmayer M, Bittencourt R, Schwartz IVD, Prada CE. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. Am J Med Genet C Semin Med Genet. 2020 12; 184(4):1052-1059.
-
Ramos JM, Hough AJ. Plasma cell myeloma in a patient with Gaucher disease. Blood. 2019 01 03; 133(1):100.
-
Oliver R, Sallam AB, Uwaydat SH. Retinal Deposits in a Young Woman. JAMA Ophthalmol. 2018 06 01; 136(6):708-709.
-
Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017 Sep; 92(9):929-939.
-
Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, K?hl J, Grabowski GA. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017 04 27; 129(17):2375-2383.
-
Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol Genet Metab. 2017 Jan - Feb; 120(1-2):111-115.
-
Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016 Feb; 117(2):95-103.
-
Kattoor AJ, Bauer TW, Berkowitz M, Polster JM, Lichtin AE. Ankle pain in a young woman with Gaucher disease. Cleve Clin J Med. 2015 Sep; 82(9):607-13.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015 Jun 13; 385(9985):2355-62.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|